Condition
Neuroblastoma (NB) clinical trials and research
As of November 12, 2026, Find a Trial lists 6 Neuroblastoma (NB) clinical trials that are recruiting, at sites in 3 countries (most in China (4), Iran (1), Russia (1)). By phase: Phase 1 (1), Phase 2 (1), Early Phase 1 (1), Phase 1/2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 6Clinical trials
- 3Countries
Newest Neuroblastoma (NB) clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Targeted radiopharmaceutical radiotherapy for relapsed or refractory neuroblastoma | Early Phase 1 | Chengdu, Sichuan | Recruiting | Aug 17, 2026 |
| Chemoimmunotherapy with autologous NK‑cell therapy for children with refractory or relapsed high‑risk neuroblastoma and ganglioneuroblastoma | Phase 3 | Moscow | Recruiting | Jan 29, 2026 |
| Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for relapsed or refractory neuroblastoma in children | Phase 2 | Tianjin, Tianjin Municipality | Recruiting | Jan 6, 2026 |
| MIBG SPECT/CT and somatostatin receptor PET for diagnosing and staging neuroblastoma | — | Nanjing, Jiangsu | Recruiting | Jul 15, 2025 |
| CAR-T cell therapy for relapsed neuroblastoma and desmoplastic small round cell tumors | Phase 1/2 | Guangzhou, Guangdong and 2 other locations | Recruiting | Feb 20, 2025 |
| Using NK cells to treat high-risk neuroblastoma in children | Phase 1 | Tehran | Recruiting | Nov 5, 2024 |
All recruiting trials (6)
-
Targeted radiopharmaceutical radiotherapy for relapsed or refractory neuroblastoma
A short, patient-friendly test of [211At]MABG radiotherapy to see if it is safe and tolerable in kids and young patients with relapsed or hard-to-treat neuroblastoma.
-
Chemoimmunotherapy with autologous NK‑cell therapy for children with refractory or relapsed high‑risk neuroblastoma and ganglioneuroblastoma
This treatment will test whether adding a child's own expanded natural killer (NK) cells to chemoimmunotherapy helps children with refractory or relapsed high‑risk neuroblastoma or ganglioneuroblastoma respond better.
-
Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for relapsed or refractory neuroblastoma in children
This trial tests a four-drug combination to see if it can control neuroblastoma in children whose disease has come back or not responded to treatment.
-
MIBG SPECT/CT and somatostatin receptor PET for diagnosing and staging neuroblastoma
This study tests whether combining 123I‑MIBG SPECT/CT and somatostatin receptor PET improves detection, staging, and identification of PRRT candidates among children with suspected or confirmed neuroblastoma.
-
CAR-T cell therapy for relapsed neuroblastoma and desmoplastic small round cell tumors
This study is testing a new CAR-T cell therapy to see if it can help people with relapsed neuroblastoma and desmoplastic small round cell tumors feel better and improve their chances of survival.
-
Using NK cells to treat high-risk neuroblastoma in children
This study is testing if injections of special immune cells can help children aged 2 to 16 with tough-to-treat neuroblastoma feel better and improve their chances of recovery.
Related topics
Quick answers
How many Neuroblastoma (NB) clinical trials are recruiting right now?
6, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 3 countries. The most sites are in China (4 trials), Iran (1 trial), Russia (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 1, Phase 2: 1, Early Phase 1: 1, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.